Eli Lilly and Company (NYSE:LLY) Shares Purchased by Bay Colony Advisory Group Inc d b a Bay Colony Advisors

Bay Colony Advisory Group Inc d b a Bay Colony Advisors increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 34.6% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 7,286 shares of the company’s stock after purchasing an additional 1,872 shares during the period. Eli Lilly and Company accounts for approximately 0.8% of Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ investment portfolio, making the stock its 22nd biggest position. Bay Colony Advisory Group Inc d b a Bay Colony Advisors’ holdings in Eli Lilly and Company were worth $4,247,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Simon Quick Advisors LLC raised its position in shares of Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after purchasing an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $363,000. WASHINGTON TRUST Co raised its holdings in Eli Lilly and Company by 16.5% in the 4th quarter. WASHINGTON TRUST Co now owns 18,892 shares of the company’s stock valued at $11,013,000 after acquiring an additional 2,671 shares during the last quarter. Liontrust Investment Partners LLP acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at about $8,326,000. Finally, Redhawk Wealth Advisors Inc. raised its holdings in Eli Lilly and Company by 0.9% in the 3rd quarter. Redhawk Wealth Advisors Inc. now owns 6,986 shares of the company’s stock valued at $3,752,000 after acquiring an additional 65 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of Eli Lilly and Company stock in a transaction on Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the sale, the insider now directly owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 133,785 shares of company stock worth $86,537,034 in the last ninety days. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Down 1.0 %

NYSE:LLY traded down $7.95 during midday trading on Friday, hitting $751.64. 2,495,037 shares of the company were exchanged, compared to its average volume of 2,285,401. The company has a fifty day simple moving average of $761.77 and a 200 day simple moving average of $653.35. Eli Lilly and Company has a fifty-two week low of $367.35 and a fifty-two week high of $800.78. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $714.18 billion, a PE ratio of 129.59, a price-to-earnings-growth ratio of 1.65 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the business earned $2.09 EPS. Eli Lilly and Company’s revenue for the quarter was up 28.1% compared to the same quarter last year. As a group, equities analysts anticipate that Eli Lilly and Company will post 12.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent research reports. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. DZ Bank cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target for the company. in a research note on Wednesday, February 21st. The Goldman Sachs Group increased their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, BMO Capital Markets increased their price target on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.